Analysis of Drug-Induced Gastrointestinal Obstruction and Perforation Using the Japanese Adverse Drug Event Report Database

Drug-induced gastrointestinal obstruction (DIGO) and gastrointestinal perforation (DIGP) may be the result of gastrointestinal hypomotility and severe constipation, which may lead to potentially fatal complications of bowel ischemia, sepsis and perforation. We evaluated the onset profile of DIGs (DI...

Full description

Saved in:
Bibliographic Details
Main Authors: Riko Satake (Author), Kiyoka Matsumoto (Author), Mizuki Tanaka (Author), Ririka Mukai (Author), Kazuyo Shimada (Author), Yu Yoshida (Author), Misaki Inoue (Author), Shiori Hasegawa (Author), Kazuhiro Iguchi (Author), Hiroaki Ikesue (Author), Shinya Shimizu (Author), Shohei Nishida (Author), Akio Suzuki (Author), Tohru Hashida (Author), Mitsuhiro Nakamura (Author)
Format: Book
Published: Frontiers Media S.A., 2021-07-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_f1ca7711f9984fa2a32473bbf0839a27
042 |a dc 
100 1 0 |a Riko Satake  |e author 
700 1 0 |a Kiyoka Matsumoto  |e author 
700 1 0 |a Mizuki Tanaka  |e author 
700 1 0 |a Ririka Mukai  |e author 
700 1 0 |a Kazuyo Shimada  |e author 
700 1 0 |a Yu Yoshida  |e author 
700 1 0 |a Misaki Inoue  |e author 
700 1 0 |a Shiori Hasegawa  |e author 
700 1 0 |a Shiori Hasegawa  |e author 
700 1 0 |a Kazuhiro Iguchi  |e author 
700 1 0 |a Hiroaki Ikesue  |e author 
700 1 0 |a Shinya Shimizu  |e author 
700 1 0 |a Shohei Nishida  |e author 
700 1 0 |a Akio Suzuki  |e author 
700 1 0 |a Tohru Hashida  |e author 
700 1 0 |a Mitsuhiro Nakamura  |e author 
245 0 0 |a Analysis of Drug-Induced Gastrointestinal Obstruction and Perforation Using the Japanese Adverse Drug Event Report Database 
260 |b Frontiers Media S.A.,   |c 2021-07-01T00:00:00Z. 
500 |a 1663-9812 
500 |a 10.3389/fphar.2021.692292 
520 |a Drug-induced gastrointestinal obstruction (DIGO) and gastrointestinal perforation (DIGP) may be the result of gastrointestinal hypomotility and severe constipation, which may lead to potentially fatal complications of bowel ischemia, sepsis and perforation. We evaluated the onset profile of DIGs (DIGO and DIGP) associated with prescription drugs by analyzing data in the Japanese Adverse Drug Event Report (JADER) database. We selected 161 DIG-related drugs and categorized them into 19 classes based on the Anatomical Therapeutic Chemical (ATC) Classification System. Finally, we focused on 58 drugs and conducted subsequent analyses for the time-to-onset and outcomes. We extracted 79 preferred terms (PTs) with the strings "ileus," "stenosis," "obstruction," "obstructive," "impaction," "perforation," "perforated," "hypomotility," and "intussusception" from the Standardized Medical Dictionary for Regulatory Activities (MedDRA) Queries (SMQs) of SMQ20000104: gastrointestinal perforation, ulcer, hemorrhage, obstruction non-specific findings/procedures; SMQ20000105: gastrointestinal obstruction; and SMQ20000107: gastrointestinal perforation. Among the 667, 729 reports in the JADER database submitted between April 2004 and November 2020, we identified 11,351 occurrences of DIGs. The reporting odds ratios (RORs) (95% confidence interval) of "barium sulfate containing X-ray media," "drugs for treatment of hyperkalemia and hyperphosphatemia," and "oral bowel cleanser" were 142.0 (127.1-158.6), 25.8 (23.1-28.8), and 29.7 (24.8-35.6), respectively. The median number of days (interquartile range) until the onset of an adverse event caused by each drug category was as follows: barium sulfate containing X-ray contrast media [2.0 (1.0-3.0)], diazepines, oxazepines, thiazepines, and oxepines [8.0 (8.0-18.5)], drugs for treatment of hyperkalemia and hyperphosphatemia [29.0 (8.0-55.0)], non-selective monoamine reuptake inhibitors [19.0 (7.0-47.5)], and oral bowel cleanser [0.0 (0.0-0.0)]. Depending on the drug, the time to onset of side effects ranged from days to several months. Our results highlighted the need to perform detailed monitoring of each drug for possible association with DIGs, which might otherwise have fatal consequences. 
546 |a EN 
690 |a The Japanese Adverse Drug Event Report 
690 |a gastrointestinal obstruction 
690 |a gastrointestinal perforation 
690 |a ileus 
690 |a pharmacovigilance 
690 |a time-to-onset profile 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Frontiers in Pharmacology, Vol 12 (2021) 
787 0 |n https://www.frontiersin.org/articles/10.3389/fphar.2021.692292/full 
787 0 |n https://doaj.org/toc/1663-9812 
856 4 1 |u https://doaj.org/article/f1ca7711f9984fa2a32473bbf0839a27  |z Connect to this object online.